European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading

MT Newswires Live06-26

European equities traded in the US as American depositary receipts were trending lower late Wednesday morning, falling 0.85% to 1,421.90 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by internet browser company Opera (OPRA) and software firm SAP (SAP), which rose 1.9% and 1.6%, respectively. They were followed by biopharmaceutical company MorphoSys (MOR) and 3D printer company Materialise (MTLS), which were up 1.1% and 1%, respectively.

The decliners from continental Europe were led by biopharmaceutical firm Cellectis (CLLS), which fell 4.2%, followed by pharmaceutical company Sanofi (SNY), which lost 3%. They were followed by pharmaceutical company Ascendis Pharma (ASND), which retreated 2.4%, and oil and gas company TotalEnergies (TTE), which was down 2.2%.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics (AKTX) and TC Biopharm (TCBP), which increased 3.2% and 2.7%, respectively. Cruise line operator Carnival (CUK) was up 2.6% and biopharmaceutical firm Amarin (AMRN) added 1.6%.

The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN), which declined 4.3%, and then biotech firm Trinity Biotech, which lost 3.1%. They were followed by biopharmaceutical companies Mereo BioPharma Group (MREO) and Adaptimmune Therapeutics (ADAP), which fell 3% and 2.5%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment